Indian Journal of Medical Microbiology Home 

SPECIAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2018  |  Volume : 36  |  Issue : 3  |  Page : 334--343

Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India

Balaji Veeraraghavan1, Agila Kumari Pragasam1, Yamuna Devi Bakthavatchalam1, Shalini Anandan1, V Ramasubramanian2, Subramanian Swaminathan3, Ram Gopalakrishnan2, Rajeev Soman4, OC Abraham5, Vinod C Ohri6, Kamini Walia6 
1 Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India
2 Department of Infectious Diseases, Apollo Hospital, Chennai, Tamil Nadu, India
3 Department of Infectious Diseases, Global Hospital, Chennai, Tamil Nadu, India
4 Department of Infectious Diseases, PD Hinduja Hospital, Mumbai, Maharashtra, India
5 Department of Medicine (Unit -1), Christian Medical College, Vellore, Tamil Nadu, India
6 Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India

Correspondence Address:
Dr. Kamini Walia
Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi
India

Antimicrobial resistance (AMR) is a major public health concern across the globe, and it is increasing at an alarming rate. Multiple classes of antimicrobials have been used for the treatment of infectious diseases. Rise in the AMR limits its use and hence the prerequisite for the newer agents to combat drug resistance. Among the infections caused by Gram-negative organisms, beta-lactams are one of the most commonly used agents. However, the presence of diverse beta-lactamases hinders its use for therapy. To overcome these enzymes, beta-lactamase inhibitors are being discovered. The aim of this document is to address the burden of AMR in India and interventions to fight against this battle. This document addresses and summarises the following: The current scenario of AMR in India (antimicrobial susceptibility, resistance mechanisms and molecular epidemiology of common pathogens); contentious issues in the use of beta-lactam/beta-lactamase inhibitor as an carbapenem sparing agent; role of newer beta-lactam/beta-lactamase inhibitor agents with its appropriateness to Indian scenario and; the Indian Council of Medical Research interventions to combat drug resistance in terms of surveillance and infection control as a national response to AMR. This document evidences the need for improved national surveillance system and country-specific newer agents to fight against the AMR.

How to cite this article:
Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Anandan S, Ramasubramanian V, Swaminathan S, Gopalakrishnan R, Soman R, Abraham O C, Ohri VC, Walia K. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.Indian J Med Microbiol 2018;36:334-343

How to cite this URL:
Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Anandan S, Ramasubramanian V, Swaminathan S, Gopalakrishnan R, Soman R, Abraham O C, Ohri VC, Walia K. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India. Indian J Med Microbiol [serial online] 2018 [cited 2020 Sep 22 ];36:334-343
Available from: http://www.ijmm.org/article.asp?issn=0255-0857;year=2018;volume=36;issue=3;spage=334;epage=343;aulast=Veeraraghavan;type=0